Hemoteq's Fancy New Coat
Hemoteq's hemocompatible coating for medical devices could help address one of the last remaining concerns about drug-eluting stents: the risk of subacute and late thrombosis. But for a small company to compete in drug-eluting stents isn't easy.
You may also be interested in...
Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).
Boston Scientific has filed suite in the Netherlands to keep Conor Medsystems from selling its paclitaxel-coated stent in Europe. This is the latest effort by interventional cardiology companies to use litigation to protect market share.
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.